## **Terminology Issues**

Ronald C. Petersen, PhD, MD

**Cora Kanow Professor** 

of Alzheimer's Disease Research

**Mayo Clinic College of Medicine** 

Rochester, MN

Research Summit on Dementia Care

NIH

**October 17, 2017** 



MANUFACTURED 1 MANUFACTURE

### **Disclosures**

- · Roche, Inc.
- · Merck, Inc.
- · Genentech, Inc.
- Biogen, Inc.
- Eli Lilly and Co.

- National Institute on Aging:
- U01 AG006786
- P50 AG016574
- U01 AG011378
- R01 AG011378
- R01 AG041581
- GHR Foundation
- Mayo Foundation for Education and Research



02017 MFMER | 3636715-7

## Terminology Issues Complex topic Many stakeholders Scientific accuracy Sensitivity to patients and families Communication priorities Eligibility for services Delivery of services



## Conceptual Issues

- Clinical spectrum
  - Cognitively unimpaired
  - Mild cognitive impairment
  - Dementia
- Neuropathological spectrum
  - Disease elements
  - Abnormal proteins



2017 MFMER | 3838715-1

## **Specific Terms**

- Dementia
- Mild cognitive impairment
- · Alzheimer's disease
- Lewy body disorders
- Frontotemporal degeneration
- Vascular cognitive impairment-dementia
- Neurocognitive disorders
- Multifactorial-combination disorders



D2017 MFMER | 3636715-11

# Changing Terminology? • Alzheimer's disease has been a clinical-pathological entity for over 30 years • Discussions underway to redefine it as a biological entity based on its fundamental pathological features • What about FTD (FTLD), LBD, VCID? • Clinical spectrum











